Contents lists available at ScienceDirect



Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Receptor agonists of macrophage migration inhibitory factor

William L. Jorgensen ^{a,*}, Sunilkumar Gandavadi ^a, Xin Du ^b, Alissa A. Hare ^a, Alexander Trofimov ^a, Lin Leng ^b, Richard Bucala ^{b,*}

^a Department of Chemistry, Yale University, New Haven, CT 06520, USA

^b Department of Medicine, Yale University School of Medicine, New Haven, CT 06520-8031, USA

ARTICLE INFO

Article history: Received 3 August 2010 Revised 21 September 2010 Accepted 23 September 2010 Available online 29 September 2010

Keywords: MIF Cytokine Agonists Structure-based design AMPK activation ERK phosphorylation Click chemistry

ABSTRACT

The cytokine MIF is involved in inflammation and cell proliferation via pathways initiated by its binding to the transmembrane receptor CD74. MIF also promotes AMPK activation with potential benefits for response to myocardial infarction and ischemia-reperfusion. Structure-based molecular design has led to the discovery of not only antagonists, but also the first agonists of MIF–CD74 binding. The compounds contain a triazole core that is readily assembled via Cu-catalyzed click chemistry. The agonist and antagonist behaviors were confirmed via study of MIF-dependent ERK1/2 phosphorylation in human fibroblasts. © 2010 Elsevier Ltd. All rights reserved.

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that is expressed in multiple cell types including macrophages, endothelial cells, T-cells, and cardiomyocytes. It is involved in the pathogenesis of inflammatory diseases as well as in tumor growth and angiogenesis. The potential biomedical significance of MIF regulation is under active investigation.¹⁻³ MIF signal transduction is initiated by binding to a receptor complex consisting of CD74 and CD44.⁴⁻⁶ Though emphasis has been placed on discovery of antagonists of MIF signaling,¹⁻³ report of agonists would be valuable both as probes of MIF biology and in therapeutic indications. For example, MIF activation leads to an immune adjuvant effect.⁷ Furthermore, it has recently been shown that MIF stimulates the AMP-activated protein kinase (AMPK) in heart muscle.⁸ AMPK plays a central role in cardiac response to ischemia through promoting glucose uptake and limiting myocardial injury and apoptosis.9 Since AMPK deficiency is deleterious during ischemiareperfusion, MIF-CD74 agonism also provides a potential therapy for acute myocardial ischemia via enhanced AMPK activation.⁸ Enhancement of MIF signaling and AMPK activity in limiting cardiac damage may be especially beneficial for older patients.¹⁰

Besides being a cytokine, MIF shows enzymatic activity as a keto-enol tautomerase, which is likely vestigial in mammals.¹¹ The 114-residue MIF monomer associates to form a symmetrical

trimer with three tautomerase active sites (Fig. 1).^{2,12,13} Though there is evidence that the MIF–CD74 contact occurs in the vicinity



Figure 1. 1GCZ crystal structure (1.9 Å) for the MIF trimer with three copies of chromene derivative **1** (space-filling) in the active sites.

^{*} Corresponding authors. Tel.: +1 203 432 6278; fax: +1 203 432 6299 (W.L.J.). *E-mail addresses*: william.jorgensen@yale.edu (W.L. Jorgensen), richard.bucala@ yale.edu (R. Bucala).

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter \odot 2010 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2010.09.118

of the tautomerase active site,¹⁴ no crystal structure for a MIF-CD74 complex has been reported. Nevertheless, the availability of crystal structures for MIF has enabled structure-based discovery of small-molecule MIF tautomerase inhibitors.^{1,3} In conjunction with a protein–protein binding assay,⁴ it has also been possible to discover inhibitors of the more biologically significant MIF–CD74 complexation. Indeed, virtual screening by docking led to our identification of 11 structurally diverse inhibitors of MIF–CD74 binding with activities in the μ M regime.¹⁵ Optimization of one series, featuring a *N*-benzyl-benzoxazol-2-one core, has provided compounds with IC₅₀ values as low as 7.5 nM in the tautomerase assay and 80 nM in the MIF–CD74 binding assay.¹⁶

In parallel with the docking investigations, de novo design also was pursued using the program *BOMB*,¹⁷ which can build combinatorial libraries of analogs starting from a core placed in a binding site. Common features were apparent in available crystal structures for MIF complexed with the chromene analog $1^{2,18}$ and the dihydroisoxazole **2** ((*R*)-ISO-1),¹³ which are both reported to be 7 μ M tautomerase inhibitors. The crystal structures feature a hydrogen bond between the phenolic OH of the inhibitors and the side-chain CO of Asn97, which forms a backstop for the active site. There is also the potential for additional hydrogen-bonding with the NH of lle64 and OH of Tyr95 as well as aryl–aryl interactions with Tyr36, Tyr95, and Phe113.



Thus, using phenol as the core hydrogen-bonded to Asn97, libraries were constructed in the motif HOPhHetR where Het is a 5- or 6-membered heterocycle and R is a small substituent. Roughly 100 choices for Het and 50 for R were initially considered using *BOMB*. Among well-scoring alternatives for Het, pyrazoles and triazoles were promising as were various aryl, CH₂Ar, and OAr options for R. Since facile synthesis of 1,2,3-triazole derivatives was envisaged,¹⁹ they became the focus. For example, the dimethoxybenzyl derivative in Figure 2 could be constructed to yield a striking complex including hydrogen bonds with Asn97 and Tyr95, π - π interactions with Tyr95 and Phe113, and possible cation– π and/or cation–ether interactions with Lys32.

Substituted 1.2.3-triazoles were pursued in four series corresponding to structures **3**, **4**, **5**, and **6**. These represent two pairs of isomers, which are either 4-hydroxyphenyl substituted at the 1- or 4-position and with either a benzyl or heteroaryl group at the other site. The synthetic routes are summarized in Scheme 1. For the Cu(I)-catalyzed 1,3-dipolar cycloadditions,¹⁹ a one-pot protocol utilizing terminal alkynes and in situ formation of aryl or benzyl azides from the corresponding bromides or iodides was highly effective.²⁰ The typical procedure used 10 mol % Cul, 10 mol % sodium ascorbate, and 15 mol % *trans-N*,N'-dimethyl-1,2-cyclohexanediamine as ligand at 25–75 °C under argon. Compounds of types 3, 5, and 6 were readily accessible, while for 4 avoidance of benzyl acetylenes required a longer sequence featuring a Grignard reaction, catalytic hydrogenation of the resulting alcohol, and hydrolysis of the THP ether. Most reactions proceeded in 70-100% yield. The identity of all assayed compounds was confirmed by ¹H (Bruker DRX-500) and ¹³C NMR and HRMS; purity was normally >95% as determined by reverse-phase HPLC.

The MIF–CD74 binding assay was performed as previously presented.^{4,15} It features biotinylated MIF and immobilized CD74 ectodomain (CD74^{73–232}) with streptavidin conjugated alkaline phosphatase processing *p*-nitrophenylphosphate as the reporter. Most compounds also were evaluated in a MIF tautomerase assay using 4-hydroxyphenylpyruvate (4-HPP) as the substrate.^{15,21} Compounds were tested at concentrations between 1 nM and 1 mM using human MIF, which was recombinantly prepared.²²

The assay results are summarized in Table 1. In cases where some inhibition is observed, but it plateaus without reaching the 50% level, the maximum percent inhibition is reported. Such maxima were normally reached below 0.5 μ M in the binding assay and in the μ M range for the tautomerase assay. As discussed previously,¹⁵ a simple correlation between the results for the two assays is not expected. Docking calculations for all of the complexes were also carried out using *Glide* 5.5 in the extra precision (XP) mode.²³ In previous studies, it was demonstrated that *Glide* XP scores correlated well with experimental log K_i or log IC₅₀ values for complexes of 10 known MIF tautomerase inhibitors.^{15,16} The most favorable XP score, -9.4, for the known inhibitors is for a coumarin derivative with a reported K_i of 38 nM,² and inhibitors with K_i values near 1 μ M gave XP scores near -9.0. In comparing these results to the XP scores in Table 1, most of the triazole derivatives were



Figure 2. Computed structure for 3g bound to MIF from BOMB after energy minimization using MCPRO and the OPLS/CM1A force field.



Scheme 1. Synthesis of aryl-1,2,3-triazoles.

Table 1

Activities for 1,2,3-triazole derivatives from the MIF-CD74 and tautomerase (4-HPP) assays, and Glide XP scores^a

Compd	X or Ar	IC ₅₀ or max % inhib		XP Score
		CD74	4-HPP	
3a	_	NA		-7.2
3b	2-Me	NA		-7.0
3c	3-Me	NA		-7.2
3d	2-OMe	Agon	Agon	-6.9
3e	3-OMe	50		-7.4
3f	4-OMe	NA		-7.2
3g	2,3-diOMe	0.9	0.75	-7.9
3h	3-COOMe	1.2	2.5	-7.3
3i	3-COOH	NA		-7.6
4a	_	3.5		-6.7
4b	3-Me	30%	475	-6.8
4c	2-0H	9%	1000	-7.0
4d	3-0H	NA	NA	-6.8
4e	4-0H	23%	690	-6.7
4f	2-OMe	14%	35%	-6.4
4g	3-OMe	8%	40%	-6.5
4h	4-OMe	36%	65	-6.0
4i	2,3-diOMe	NA	530	-7.1
4j	3,4-diOMe	22%	70	-6.6
5a	3-Pyridinyl	Agon	Agon	-6.5
5b	1-Naphthyl	NA		-5.9
5c	4-Isoquinolinyl	Agon	Agon	-6.0
6a	3-Pyridinyl	16%	970	-7.1
6b	1-Naphthyl	23%		-6.4
6c	4-Isoquinolinyl	12%	32	-6.0
6d	CH ₂ -2-pyridinyl	30%		-7.3
6e	CH ₂ -3-pyridinyl	20%		-7.3

 $[^]a~IC_{50}$ in $\mu M.$ NA = inactive. Agon = agonist. XP scores from Glide v. 5.5 using the 1GCZ structure for MIF.

not expected to be strong MIF tautomerase inhibitors. The exceptions turned about to be **3g** and **3h**, which yielded IC_{50} values of 0.75 and 2.5 μ M. As illustrated in Figure 2, the binding of **3g** to MIF may be enhanced by coordination of the ammonium group of Lys32 with the 2,3-dimethoxyl fragment of **3g**.

Compounds **3g** and **3h** also emerged as the most potent antagonists in the MIF-CD74 binding assay with IC_{50} values near 1 μ M. However, the most remarkable discovery was that **3d**, **5a**, and **5c** increase the amount of MIF that remains bound to CD74 after washing. The increase in bound MIF depends linearly on the log of the agonist concentration. For **3d**, there is a 40% increase in bound MIF at 500 nM, while there are 100% increases for **5a** and **5c** at ca. 100 nM and 150 nM, respectively. The contrasting behaviors for the antagonist **3g** and agonist **5a** are striking in Figure 3. The three compounds were also agonists in the tautomerase assay with the activity increasing by 31%, 23%, and 39% at



Figure 4. Computed structure for **5a** bound to MIF. Details as in Figure 2. Negligible energetic preference is computed for the triazole ring being oriented up as shown or down (rotated 180°).

100 nM for **3d**, **5a**, and **5c**, but not increasing significantly more at higher concentrations.



It would be fascinating to know the structural origins of the agonist behavior for the three compounds. Reasonable structures can be built for them bound in the tautomerase active site, as in Figure 4. For the tautomerase activity, it is possible that binding in one active site could enhance allosterically the activity in another site. It is also possible that the molecules bind to an alternative surface site that leads to the agonist character in both assays.^{18,24} Experimental structural studies are clearly desirable. It may be noted that small changes in a ligand have also been shown recently to interconvert agonist and antagonist character for the protein-protein association of Hsp40 and Hsp90.²⁵

Finally, the potentially contrasting effects of the MIF agonists **3d**, **5a**, and **5c** versus the MIF antagonist **3g** on MIF signal transduction were explored in human target cells. The extracellular-signal-regulated kinase (ERK) pathway is of particular interest as aberrations in it are associated with hyperproliferative diseases as well as inflammatory disorders. Up-regulation of MIF increases ERK1/2 phosphorylation in a CD74-dependent manner.⁴ Specifically, human primary



Figure 3. Results of the MIF-CD74 binding assays for the antagonist 3g (left) and agonist 5a (right).



Figure 5. Effects of the agonists on MIF-dependent ERK1/2 phosphorylation in human fibroblasts. The upper panel displays a representative western blot and the lower panel shows the numerical ratio of phosphorylated to total kinase protein determined by densitometric scanning for three separate experiments. * P <0.05.



Figure 6. Effect of antagonist **3g** on MIF-dependent ERK1/2 phosphorylation in human fibroblasts. The upper panel displays a representative western blot and the lower panel shows the numerical ratio of phosphorylated to total kinase protein determined by densitometric scanning for three separate experiments. $*^{**}P < 0.0025$.

fibroblasts were incubated with MIF (2.7 nM trimer) together with vehicle control (DMSO) or with **3d**, **5a**, or **5c** (each at 8 nM) for 30 min. The cells then were lysed and the intracellular contents of phospho-ERK1/2 and total ERK1/2 were detected by specific antibodies and western blotting (Fig. 5). The addition of these compounds to MIF enhances ERK1/2 phosphorylation,⁴ while co-incubation of antagonist **3g** under the same experimental conditions strongly inhibits the process (Fig. 6).

In summary, de novo design of small molecules to bind to the MIF tautomerase active site was carried out using the program *BOMB* and led to pursuit of aryl-1,2,3-triazole derivatives. Two ca. 1 μ M tautomerase inhibitors, **3g** and **3h**, were discovered that

also showed $1-\mu M$ potency in inhibiting the binding of MIF to its receptor CD74. Most significantly, three molecules, **3d**, **5a**, and **5c**, were discovered that enhance the binding of MIF and CD74. The contrasting antagonist and agonist behaviors of **3g** versus **3d**, **5a**, and **5c** were then confirmed by monitoring the MIF-dependent phosphorylation of ERK kinases in human fibroblasts. The potential utility of the newly discovered agonists extends from fundamental studies of the biology of MIF to therapeutic applications as immune adjuvants or in limiting ischemic cardiac injury.

Acknowledgements

Gratitude is expressed to the National Institutes of Health (AI042310, AR049610, AR050498, GM032136) and the Treat B. Johnson Fund at Yale for support.

References and notes

- 1. Bucala, R. Nature 2000, 408, 146.
- 2. Orita, M.; Yamamoto, S.; Katayama, N.; Fujita, S. Curr. Pharm. Des. 2002, 8, 1297.
- 3. Garai, J.; Lorand, T. Curr. Med. Chem. 2009, 16, 1091.
- Leng, L.; Metz, C. N.; Fang, Y.; Xu, J.; Donnelly, S.; Baugh, J.; Delohery, T.; Chen, Y.; Mitchell, R. A.; Bucala, R. J. Exp. Med. 2003, 197, 1467.
- Shi, X.; Leng, L.; Wang, T.; Wang, W.; Du, X.; Li, J.; McDonald, C.; Chen, Z.; Murphy, J. W.; Lolis, E.; Noble, P.; Knudson, W.; Bucala, R. *Immunity* 2006, 25, 595.
- Meyer-Siegler, K. L.; Iczkowski, K. A.; Leng, L.; Bucala, R.; Vera, P. L. J. Immunol. 2006, 177, 8730.
- Bacher, M.; Metz, C. N.; Calandra, T.; Mayer, K.; Chesney, J.; Lohoff, M.; Gemsa, D.; Donnelly, T.; Bucala, R. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7849.
- Miller, E. J.; Li, J.; Leng, L.; McDonald, C.; Atsumi, T.; Bucala, R.; Young, L. H. Nature 2008, 451, 578.
- Russell, R. R., III; Li, J.; Coven, D. L.; Pypaert, M.; Zechner, C.; Palmeri, M.; Giordano, F. J.; Mu, J.; Birnbaum, M. J.; Young, L. H. J. Clin. Invest. 2004, 114, 495.
- Ma, H.; Wang, J.; Thomas, D. P.; Tong, C.; Leng, L.; Wang, W.; Merk, M.; Zierow, S.; Bernhagen, J.; Ren, J.; Bucala, R.; Li, J. *Circulation* **2010**, *122*, 282.
 Fingerle-Rowson, G.; Kaleswarapu, D. R.; Schlander, C.; Kabgani, N.; Brocks, T.;
- Fingerle-Rowson, G.; Kaleswarapu, D. R.; Schlander, C.; Kabgani, N.; Brocks, T.; Reinart, N.; Busch, R.; Schütz, A.; Lue, H.; Du, X.; Liu, A.; Xiong, H.; Chen, Y.; Nemajerova, A.; Hallek, M.; Bernhagen, J.; Leng, L.; Bucala, R. *Mol. Cell Biol.* 2009, 29, 1922.
- 12. Lubetsky, J. B.; Swope, M.; Dealwis, C.; Blake, P.; Lolis, E. Biochemistry 1999, 38, 7346.
- Lubetsky, J. B.; Dios, A.; Han, J.; Aljabari, B.; Ruzsicska, B.; Mitchell, R.; Lolis, E.; Al-Abed, Y. *J. Biol. Chem.* **2002**, 277, 24976.
 Senter, P. D.; Al-Abed, Y.; Metz, C. N.; Benigni, F.; Mitchell, R. A.; Chesney, J.;
- Senter, P. D.; Al-Abed, Y.; Metz, C. N.; Benigni, F.; Mitchell, R. A.; Chesney, J.; Han, J.; Gartner, C. G.; Nelson, S. D.; Todaro, G. J.; Bucala, R. *Proc. Natl. Acad. Sci.* U.S.A. 2002, 99, 144.
- 15. Cournia, Z.; Leng, L.; Gandavadi, S.; Du, X.; Bucala, R.; Jorgensen, W. L. J. Med. Chem. 2009, 52, 416.
- Hare, A. A.; Leng, L.; Gandavadi, S.; Du, X.; Cournia, Z.; Bucala, R.; Jorgensen, W. L. Bioorg. Med. Chem. Lett. 2010, 20, 5811.
- 17. Jorgensen, W. L. Acc. Chem. Res. 2009, 42, 724-733.
- McLean, L. R.; Zhang, Y.; Li, H.; Choi, Y.-M.; Han, Z.; Vaz, R. J.; Li, Y. Bioorg. Med. Chem. Lett. 2010, 20, 1821.
- Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int. Ed. 2002, 41, 2596.
- 20. Andersen, J.; Bolvig, S.; Liang, X. Synlett 2005, 2941.
- Stamps, S. L.; Taylor, A. B.; Wang, S. C.; Hackert, M. L.; Whitman, C. P. Biochemistry 2000, 39, 9671.
- Bernhagen, J.; Mitchell, R. A.; Calandra, T.; Voelter, W.; Cerami, A.; Bucala, R. Biochemistry 1994, 33, 14144.
- Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. J. Med. Chem. 2006, 49, 6177.
- Cho, Y.; Crichlow, G. V.; Vermeire, J. J.; Leng, L.; Du, X.; Hodsdon, M. E.; Bucala, R.; Cappello, M.; Gross, M.; Gaeta, F.; Johnson, K.; Lolis, E. J. *Proc. Natl. Acad.* U.S.A. 2010, 107, 11313.
- Wisén, S.; Bertelsen, E. B.; Thompson, A. D.; Patury, S.; Ung, P.; Chang, L.; Evans, C. G.; Walter, G. M.; Wipf, P.; Carlson, H. A.; Brodsky, J. L.; Zuiderweg, E. R. P.; Gestwicki, J. E. ACS Chem. Biol. 2010, 5, 611.